Character Biosciences Secures $93M for Precision Therapies in Eye Diseases

Character Biosciences raises $93 million in Series B funding to advance precision therapies for degenerative eye diseases, starting with age-related macular degeneration (AMD). The company focuses on precision medicine and aims to improve drug development efficacy with a pipeline targeting dry AMD and primary open-angle glaucoma (POAG).